Cingulate Inc. (CING) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Kansas City, KS, 美国. 现任CEO为 Shane J. Schaffer.
CING 拥有 IPO日期为 2021-12-08, 13 名全职员工, 在 NASDAQ Capital Marke, 市值为 $29.15M.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
